Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis

IMPORTANCE: Clinical trials in Alzheimer disease (AD) generally allow participants to continue receiving concomitant medications, including cholinesterase inhibitors (ChEIs) and memantine, if the dose is stable. Previous analysis of observational studies indicates such individuals experience greater...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Richard E., Cutter, Gary R., Fowler, Mackenzie E., Schneider, Lon S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324361/
https://www.ncbi.nlm.nih.gov/pubmed/30646339
http://dx.doi.org/10.1001/jamanetworkopen.2018.4080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324361/
https://www.ncbi.nlm.nih.gov/pubmed/30646339
http://dx.doi.org/10.1001/jamanetworkopen.2018.4080

Ejemplares similares